BioCentury | Feb 20, 2021
Product Development

BMS turns to mechanistic diversity in early oncology pipeline

...week, BMS entered a preclinical partnership with Molecular Templates Inc....
BioCentury | Feb 19, 2021
Finance

Feb. 19 Quick Takes: New Horizon triples in Hong Kong IPO; plus Alta, Hangzhou Sciwind, Molecular Templates, BeiGene-BITT and Charles River-Cognate

...a clinical pipeline that includes treatments for metabolic and immunological disorders.Follow-on, BMS deal add to Molecular Templates’...
...announcing a partnership with Bristol Myers Squibb Co. (NYSE:BMS) that delivered $70 million up front, Molecular Templates Inc....
...will work with BMS to discover and develop therapies using Molecular Templates’  engineered toxin body platform. Molecular Templates...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...β thalassemia and sickle cell disease (see "Vertex, CRISPR Show Early Benefits with Therapy" ). Molecular Templates Inc....
...chemotherapy in patients undergoing hematopoietic stem cell transplants, including patients receiving Vertex's CTX001 (see "Vertex, Molecular Templates...
...Deals, Follow-ons Well Short of 2018's Total" ). Hongjiang Li, Staff Writer Karuna Therapeutics Inc. CRISPR Therapeutics AG OptiNose Inc. Molecular Templates Inc....
BioCentury | Nov 19, 2019
Company News

Vertex, Molecular Templates partner to improve conditioning regimens for edited cell therapies

...Vertex is collaborating with Molecular Templates to establish more targeted conditioning regimens that could replace chemotherapy in...
...regimens that could replace chemotherapy in patients undergoing hematopoietic stem cell transplants. Under the deal, Molecular Templates Inc....
...to exclusively license ETBs against the targets for development in any indication. Vertex will pay Molecular Templates...
BioCentury | Nov 19, 2019
Clinical News

Vertex, CRISPR show early benefits with therapy, but longer term data are needed to show how it stacks up

...CTX001 suggest patients treated with the therapy could benefit from Vertex's Nov. 18 deal with Molecular Templates Inc....
...conditioning regimens to replace chemotherapy in patients undergoing hematopoietic stem cell transplants (see “ Vertex, Molecular Templates...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...for relapsed or refractory MM. Through separate co-development collaborations with Teva Pharmaceutical Industries Ltd. and Molecular Templates Inc....
...linked to an attenuated version of IFNa2b, in Phase I/II testing for refractory MM. With Molecular Templates...
...A/S (CSE:GEN; Pink:GMXAY), Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Kyoto University, Kyoto, Japan Molecular Templates Inc....
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...Co. Ltd. (Tokyo, Japan), and CMO of Avanir Pharmaceuticals Inc., which Otsuka acquired. Oncology company Molecular Templates Inc....
BioCentury | Sep 28, 2018
Financial News

CRISPR, Viking, Fate, Molecular Templates price follow-ons

...CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each...
...Co. Ltd. (Tokyo:4528) to develop and commercialize two off-the-shelf CAR T cell programs for cancer. Molecular Templates...
...Molecular Templates Inc. (NASDAQ:MTEM), Austin, Texas Viking Therapeutics Inc. (NASDAQ:VKTX), San Diego, Calif. Brian Moy CRISPR Therapeutics AG Fate Therapeutics Inc. Molecular Templates Inc. Viking...
BioCentury | Sep 21, 2018
Company News

Molecular Templates extends deal with Takeda on engineered toxin bodies

...Building on a previous discovery collaboration, Molecular Templates Inc. (NASDAQ:MTEM) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered Sept...
...trial; after the trial's completion, Molecular Templates has the option to continue co-developing the candidates. If Molecular Templates...
...19. Molecular Templates Inc. (NASDAQ:MTEM), Austin, Texas Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Tokyo, Japan Business: Cancer Elizabeth S. Eaton Molecular Templates Inc. Takeda...
BioCentury | Sep 21, 2018
Financial News

Follow-on roundup: CRISPR, Viking, Fate, Molecular Templates

...CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each...
...CAR T cell programs for cancer (see "Ono, Fate in Off-the-Shelf CAR T Deal" ). Molecular Templates...
...Cowen, Evercore ISI, UBS and Laidlaw are underwriters. The price was a 12% discount to Molecular Templates'...
Items per page:
1 - 10 of 29
BioCentury | Feb 20, 2021
Product Development

BMS turns to mechanistic diversity in early oncology pipeline

...week, BMS entered a preclinical partnership with Molecular Templates Inc....
BioCentury | Feb 19, 2021
Finance

Feb. 19 Quick Takes: New Horizon triples in Hong Kong IPO; plus Alta, Hangzhou Sciwind, Molecular Templates, BeiGene-BITT and Charles River-Cognate

...a clinical pipeline that includes treatments for metabolic and immunological disorders.Follow-on, BMS deal add to Molecular Templates’...
...announcing a partnership with Bristol Myers Squibb Co. (NYSE:BMS) that delivered $70 million up front, Molecular Templates Inc....
...will work with BMS to discover and develop therapies using Molecular Templates’  engineered toxin body platform. Molecular Templates...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...β thalassemia and sickle cell disease (see "Vertex, CRISPR Show Early Benefits with Therapy" ). Molecular Templates Inc....
...chemotherapy in patients undergoing hematopoietic stem cell transplants, including patients receiving Vertex's CTX001 (see "Vertex, Molecular Templates...
...Deals, Follow-ons Well Short of 2018's Total" ). Hongjiang Li, Staff Writer Karuna Therapeutics Inc. CRISPR Therapeutics AG OptiNose Inc. Molecular Templates Inc....
BioCentury | Nov 19, 2019
Company News

Vertex, Molecular Templates partner to improve conditioning regimens for edited cell therapies

...Vertex is collaborating with Molecular Templates to establish more targeted conditioning regimens that could replace chemotherapy in...
...regimens that could replace chemotherapy in patients undergoing hematopoietic stem cell transplants. Under the deal, Molecular Templates Inc....
...to exclusively license ETBs against the targets for development in any indication. Vertex will pay Molecular Templates...
BioCentury | Nov 19, 2019
Clinical News

Vertex, CRISPR show early benefits with therapy, but longer term data are needed to show how it stacks up

...CTX001 suggest patients treated with the therapy could benefit from Vertex's Nov. 18 deal with Molecular Templates Inc....
...conditioning regimens to replace chemotherapy in patients undergoing hematopoietic stem cell transplants (see “ Vertex, Molecular Templates...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...for relapsed or refractory MM. Through separate co-development collaborations with Teva Pharmaceutical Industries Ltd. and Molecular Templates Inc....
...linked to an attenuated version of IFNa2b, in Phase I/II testing for refractory MM. With Molecular Templates...
...A/S (CSE:GEN; Pink:GMXAY), Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Kyoto University, Kyoto, Japan Molecular Templates Inc....
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...Co. Ltd. (Tokyo, Japan), and CMO of Avanir Pharmaceuticals Inc., which Otsuka acquired. Oncology company Molecular Templates Inc....
BioCentury | Sep 28, 2018
Financial News

CRISPR, Viking, Fate, Molecular Templates price follow-ons

...CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each...
...Co. Ltd. (Tokyo:4528) to develop and commercialize two off-the-shelf CAR T cell programs for cancer. Molecular Templates...
...Molecular Templates Inc. (NASDAQ:MTEM), Austin, Texas Viking Therapeutics Inc. (NASDAQ:VKTX), San Diego, Calif. Brian Moy CRISPR Therapeutics AG Fate Therapeutics Inc. Molecular Templates Inc. Viking...
BioCentury | Sep 21, 2018
Company News

Molecular Templates extends deal with Takeda on engineered toxin bodies

...Building on a previous discovery collaboration, Molecular Templates Inc. (NASDAQ:MTEM) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered Sept...
...trial; after the trial's completion, Molecular Templates has the option to continue co-developing the candidates. If Molecular Templates...
...19. Molecular Templates Inc. (NASDAQ:MTEM), Austin, Texas Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Tokyo, Japan Business: Cancer Elizabeth S. Eaton Molecular Templates Inc. Takeda...
BioCentury | Sep 21, 2018
Financial News

Follow-on roundup: CRISPR, Viking, Fate, Molecular Templates

...CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each...
...CAR T cell programs for cancer (see "Ono, Fate in Off-the-Shelf CAR T Deal" ). Molecular Templates...
...Cowen, Evercore ISI, UBS and Laidlaw are underwriters. The price was a 12% discount to Molecular Templates'...
Items per page:
1 - 10 of 29